Gentile, I.; Scotto, R.; Scirocco, M.M.; Di Brizzi, F.; Cuccurullo, F.; Silvitelli, M.; Ametrano, L.; Alfè, F.A.; Pietroluongo, D.; Irace, I.;
et al. Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study). Microorganisms 2025, 13, 669.
https://doi.org/10.3390/microorganisms13030669
AMA Style
Gentile I, Scotto R, Scirocco MM, Di Brizzi F, Cuccurullo F, Silvitelli M, Ametrano L, Alfè FA, Pietroluongo D, Irace I,
et al. Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study). Microorganisms. 2025; 13(3):669.
https://doi.org/10.3390/microorganisms13030669
Chicago/Turabian Style
Gentile, Ivan, Riccardo Scotto, Maria Michela Scirocco, Francesco Di Brizzi, Federica Cuccurullo, Maria Silvitelli, Luigi Ametrano, Francesco Antimo Alfè, Daria Pietroluongo, Irene Irace,
and et al. 2025. "Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study)" Microorganisms 13, no. 3: 669.
https://doi.org/10.3390/microorganisms13030669
APA Style
Gentile, I., Scotto, R., Scirocco, M. M., Di Brizzi, F., Cuccurullo, F., Silvitelli, M., Ametrano, L., Alfè, F. A., Pietroluongo, D., Irace, I., Chiariello, M., De Felice, N., Severino, S., Viceconte, G., Schiano Moriello, N., Maraolo, A. E., Buonomo, A. R., Giaccone, A., & on behalf of Federico II COVID Team.
(2025). Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study). Microorganisms, 13(3), 669.
https://doi.org/10.3390/microorganisms13030669